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Introduction
Diabetes mellitus (DM) has long been recognized as a
major risk factor of cardiovascular (CV) morbidity and
mortality.1 DM subjects suffer at least 2 times more
coronary heart disease (HD) and ischemic stroke mor-
tality than subjects without DM.2 DM subjects without
a prior history of myocardial infarction at baseline may
be equivalent to nondiabetic subjects with prior myo-
cardial infarction in terms of future risk for fatal and
nonfatal myocardial infarction.3 Therefore, recent
guidelines have recommended aggressive targets for
blood pressure control and management of dyslipi-
demia in all DM patients, as in patients with established
coronary HD.4,5 However, the novel concept that DM
is a coronary HD equivalent has not always been sup-
ported by subsequent epidemiological studies,6–9 and
a recent meta-analysis showed that DM subjects with-
out prior myocardial infarction have a 43% lower risk of
developing total coronary HD events compared with
nondiabetic subjects with prior myocardial infarction.2
Furthermore, it remains unclear if the concept extends
to other CV outcomes and applies to Asian popula-
tions. We hypothesized that DM is equivalent to a prior
history of HD in the prediction of CV mortality in
Chinese, and that the risk of CV mortality in DM
subjects can further be stratified by the presence of
hypertension (HT) and metabolic syndrome (MS).
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DM and cardiovascular mortality
Therefore, the aims of the present study were to inves-
tigate whether or not DM patients without prior HD
have a similar risk of CV mortality as HD without MD
(non-DM HD) patients, and whether or not the pres-
ence of HT or MS enhances CV mortality risk in DM
subjects identified from a community-based population
of homogeneous Chinese.
Methods
Baseline surveys for all residents over 30 years of age in
Kinmen County of Taiwan were performed during the
period of 1991–1995, with an overall response rate of
62.5%, based on a target population of 20,185 by
household registration.10,11 For the present study, sub-
jects with missing information in any 1 of the compo-
nents of MS were excluded; the baseline characteristics
stratified by the presence or absence of DM and HD
for the final 11,058 eligible study subjects are pre-
sented in Table 1.
Details of the data collection in the surveys have
been previously reported.10,11 Briefly, demographic
and clinical parameters were collected during face-to-
face interviews with structured questionnaires. Anthro-
pometric measurements including body weight, height,
and waist circumference were carried out with the
subjects wearing light clothing and no shoes. Three
blood pressure measurements separated by at least 
5 minutes from the right arm of subjects after they
were seated for at least 5 minutes were taken manually
using a mercury sphygmomanometer and a standard-
sized cuff by well-trained medical students or public
health nurses. Body mass index (BMI) was calculated as
weight in kilograms divided by the square of height in
meters. All participants were volunteers and had given
consent to participate in this survey. However, no writ-
ten consent forms were obtained from the participants.
Overnight fasting serum and plasma samples were
drawn for glucose, lipids, and other biochemical mea-
surements. Serum triglycerides were measured by auto-
mated enzymatic methods with a Hitachi auto-analyzer
(Hitachi, Tokyo, Japan) and Boehringer Mannheim
Diagnostics (Mannheim, Germany) reagents. Serum
high-density lipoprotein cholesterol was measured
using a precipitation method (Kodak Ektachem 
HDL Cholesterol kit; Eastman Kodak, Rochester, NY,
USA). Plasma glucose concentrations were determined
by a hexokinase/glucose-6-phosphate dehydrogenase
method (Gilford Glucose HK Reagent kit; Gilford
Systems, Oberlin, OH, USA). DM was defined as
fasting plasma glucose ≥ 126 mg/dL (7.0 mmol/L)
or on drug treatment for DM.12 HD was defined by a 
“yes” response to the questionnaire of “Do you have
HD?”. HT was defined as a systolic blood pressure
≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg
or being on drug treatment for HT.4 MS was defined
when ≥ 3 of the following 5 components were pre-
sent:13 (1) waist circumference ≥90cm in men and
≥80cm in women;14 (2) triglyceride levels ≥1.7mmol/
L (150 mg/dL); (3) high-density lipoprotein cho-
lesterol levels < 1.0 mmol/L (40 mg/dL) in men and
< 1.3mmol/L (50mg/dL) in women; (4) systolic
blood pressure ≥ 130 mmHg or diastolic blood pres-
sure ≥85mmHg, or on drug treatment for HT; (5)
fasting glucose ≥5.5mmol/L (100mg/dL) or on drug
treatment for DM. Cigarette smoking was defined by
“yes” to the question of “Do you have a habit of
smoking?”.
The dates and causes of death for those who died
within a median of 15.0 years after the baseline survey
were collected for all of the 11,058 participants by
linking our database with the National Death Registry
through a unique personal identification number.
Participants who were not present in the National
Death Registry at the study time point were considered
as surviving. The National Death Registry database
registers valid death information based on the certi-
fied death certificates for every Taiwanese person who
has been given a unique and life-long personal identi-
fication number. The death certificates were coded
according to the International Classification of Disease,
Ninth Revision (ICD-9). The relevant ICD-9 codes
used for CV death were 390–459.
Statistical analysis
Data are presented as mean± standard deviation. The
Student’s t test and χ2 test were used for between-
group comparisons when appropriate. Mortality rates
were calculated by dividing the number of deaths by the
person-years of observation. The period of observa-
tion was defined as the interval between the baseline
survey and the date of death or the last entry date of
the National Death Registry when surviving. The
Cox proportional hazards model was used to estimate
the relative risks of mortality, adjusting for covariates.
The covariates included age, sex and smoking, since
smoking is a well established risk factor of CV disease.
The percentages of current smoking differed signifi-
cantly among all groups (p = 0.0218). The Kaplan-
Meier estimate and log-rank test were used to
preliminarily compare survival curves of all-cause and
CV mortality for the subgroups. All statistical signifi-
cance was set at p < 0.05. Statistical analyses were per-
formed using the statistical package SAS version 9.1
(SAS Institute Inc., Cary, NC, USA).
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Results
There were 903 (8.17%) subjects with DM and 491
(4.44%) subjects with self-reported HD at baseline.
The mean values of waist circumference, BMI, triglyc-
erides, systolic blood pressure, diastolic blood pressure,
and the percentages of MS and HT were decreased in
the following 4 subgroups: (1) DM and HD (n = 76);
(2) subjects with DM but without HD [(non-HD
DM), n=827]; (3) HD but without DM (n=415); and
(4) without either DM or HD (n = 9,740) (Table 1, all
p < 0.05 for trend). The mean values of high-density
lipoprotein cholesterol were increased for the 4 sub-
groups (p < 0.05).
Subjects with DM but without HD had a signifi-
cantly older age, greater waist circumference and BMI,
higher levels of total cholesterol, triglycerides, low-
density lipoprotein cholesterol, and fasting plasma glu-
cose, and higher systolic and diastolic blood pressure,
prevalence of HT and smoking, and lower high-density
lipoprotein cholesterol than did subjects with HD and
non-DM (Table 1).
Among subjects with DM and non-HD, 4 sub-
groups were defined according to the presence or
absence of HT and MS. The subgroup of DM + HT
had a significantly older age, more males, and higher
systolic and diastolic blood pressure than the subgroup
of DM alone. In contrast, the subgroup of DM + MS
had a significantly older age, more males, greater waist
circumference and BMI, higher levels of triglycerides,
higher systolic blood pressure, and lower high-density
lipoprotein cholesterol levels than the subgroup of DM
alone (Table 1).
There were 1,660 total deaths (10.83 per 1,000
person-years) and 369 CV deaths (2.41 per 1,000
person-years) during the follow-up period (median:
15.0 years). Men had higher total (13.64 vs. 8.67 per
1,000 person-years, p < 0.0001) and CV (2.70 vs. 2.19
per 1,000 person-years, p = 0.0418) mortality than
women.
The 4 groups of DM and HD, DM and non-HD,
HD and non-DM, and non-DM and non-HD had
decreased total (p < 0.0001) and CV (p < 0.0001)
mortality (Table 2). The survival curves of CV death
for the 4 groups were significantly different (p value of
log-rank test < 0.0001). Compared with the group of
non-DM and non-HD, the other 3 groups of DM and
HD, DM and non-HD, and HD and non-DM had
significantly increased hazard ratios for total and CV
mortality, with or without adjustment for age, sex, and
smoking (Table 2). Compared with the group of HD
and non-DM, the groups of DM and HD, and DM and
non-HD had significantly increased adjusted hazard
ratios for total mortality (Table 2). In contrast, com-
pared with the group of HD and non-DM, the group
of DM and HD, but not the group of DM and non-
HD, had significantly increased adjusted hazard ratios
for CV mortality (Table 2).
We also carried out an analysis for the event of coro-
nary artery disease (CAD) mortality (ICD-9 codes:
410–414). Because the case numbers of CAD mortality
were very small (n = 58), the calculated hazard ratios
for CAD mortality were extremely unstable [DM and
HD: 1.12 (CAD = 1); DM and non-HD: 1.42 (CAD =
15); HD and non-DM: 0.18 (CAD = 1); non-DM
and non-HD: 0.30 (CAD = 41)]. The between-group
Table 2. Total and cardiovascular mortality and hazard ratios according to the status of diabetes mellitus and heart disease at baseline*
DM and HD Non-HD DM Non-DM HD No DM or HD
(n = 76) (n = 827) (n = 415) (n = 9,740)
PY 894 10,555 5,642 136,135
Total deaths 29 263 89 1,279
Total mortality, 1/1,000 PY 32.4 24.9 15.8 9.4
cHR (95% CI) 3.46 (2.39–5.00) 2.66 (2.33–3.04) 1.68 (1.35–2.08) 1.0 (reference)
aHR (95% CI) 2.04 (1.41–2.96) 1.62 (1.42–1.86) 1.26 (1.01–1.56) 1.0 (reference)
aHR (95% CI) 1.61 (1.06–2.46) 1.30 (1.02–1.66) 1.0 (reference)
aHR (95% CI) 1.21 (0.82–1.79) 1.0 (reference)
CV deaths 12 64 26 267
CV mortality, 1/1,000 PY 13.4 6.1 4.6 2.0
cHR (95% CI) 7.00 (3.92–12.48) 3.14 (2.39–4.12) 2.35 (1.57–3.52) 1.0 (reference)
aHR (95% CI) 3.56 (1.99–6.36) 1.64 (1.25–2.16) 1.63 (1.09–2.44) 1.0 (reference)
aHR (95% CI) 2.10 (1.05–4.17) 1.04 (0.66–1.65) 1.0 (reference)
aHR (95% CI) 2.02 (1.08–3.78) 1.0 (reference)
*Numbers in bold indicate statistical significance. DM = diabetes mellitus; HD = heart disease; PY = person-years; cHR = crude hazard ratio; CI = confidence
interval; aHR = hazard ratio adjusted for age, sex, and smoking; CV = cardiovascular.
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differences of CAD mortality rate did not reach statis-
tical significance.
The 4 subgroups of DM + HT + MS, DM + HT,
DM + MS, and DM alone had decreased CV mortality
(p = 0.0004; Table 3, Figure 1A). Compared with the
subgroup of DM alone, the subgroups of DM +
HT + MS and DM + HT but not DM + MS had signif-
icantly increased hazard ratios for total and CV mortal-
ity (Table 3). The increased hazard ratios for total and
CV mortality became non-significant when adjusted
for age, sex, and smoking status (Table 3).
When the 827 non-HD DM subjects were stratified
only by HT, subjects with DM with HT had significantly
increased adjusted hazard ratios for total (1.59; 95%
CI = 1.21–2.09) and CV (2.36; 95% CI = 1.30–4.28)
mortality when compared with subjects with DM but
without HT. The Kaplan-Meier estimate and log-rank
test for CV mortality are shown in Figure 1B. In con-
trast, when the non-HD DM subjects were stratified
only by MS, subjects with DM with MS had similar
adjusted hazard ratios for total mortality (0.95; 95%
CI = 0.71–1.26) and non-significantly increased CV
mortality (1.23; 95% CI = 0.65–2.34) when compared
with subjects with DM but without MS. The Kaplan-
Meier estimate for CV mortality was not significant
(log-rank test p value = 0.1039).
Table 3. Total and cardiovascular mortality and hazard ratios in subjects with diabetes mellitus and no heart disease according to the
status of hypertension and metabolic syndrome at baseline*
DM + HT + MS DM + HT DM + MS DM alone
(n = 389) (n = 89) (n = 195) (n = 154)
PY 4,805 1,085 2,591 2,074
Total deaths 152 36 40 35
Total mortality, 1/1,000 PY 31.6 33.2 15.4 16.9
cHR (95% CI) 1.99 (1.31–2.74) 1.99 (1.25–3.17) 0.92 (0.58–1.44) 1.0 (reference)
aHR (95% CI) 1.32 (0.90–1.92) 1.55 (0.97–2.49) 0.76 (0.48–1.20) 1.0 (reference)
CV deaths 42 8 9 5
CV mortality, 1/1,000 PY 8.7 7.4 3.5 2.4
cHR (95% CI) 3.70 (1.46–9.34) 3.14 (1.03–9.59) 1.44 (0.48–4.28) 1.0 (reference)
aHR (95% CI) 2.44 (0.95–6.26) 2.82 (0.91–8.76) 1.09 (0.36–3.29) 1.0 (reference)
*Numbers in bold indicate statistical significance. DM = diabetes mellitus; HT = hypertension; MS = metabolic syndrome; PY = person-years; cHR = crude hazard
ratio; CI = confidence interval; aHR = hazard ratio adjusted for age, sex, and smoking; CV = cardiovascular.
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Figure 1. (A) Survival curves of cardiovascular mortality among 827 subjects with diabetes mellitus (DM) and no heart disease stratified
by the presence or absence of hypertension (HT) and metabolic syndrome (MS). (B) Differential impact of HT on the survival functions
of cardiovascular mortality in subjects with DM and no heart disease.
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Discussion
In the present community-based study, subjects with
DM without self-reported HD had a similar adjusted
risk of CV mortality as subjects with self-reported HD
without DM. This finding indicates that DM imposes
a risk of CV mortality equivalent to that for the self-
reported HD in this homogeneous Chinese popula-
tion. Among subjects with DM without self-reported
HD, there appeared to be a gradient of risk for total
and CV mortality, with the highest risk in the sub-
group of DM + HT + MS, followed by DM + HT. The
presence of HT but not MS substantially increased
the risk of CV mortality in subjects with DM without
self-reported HD.
Although there have been many studies investi-
gating the role of DM as a CV disease equivalent, 
discrepant results have been reported because of dif-
ferences in the characteristics of the study population,
follow-up duration, criteria for the diagnosis of coro-
nary HD or CV disease.2 Briefly, studies in the Finnish
population,15 Scottish men,16 and American women17
suggested that patients with non-HD DM have a sim-
ilar CV disease risk as non-DM HD patients. In con-
trast, the Atherosclerosis Risk in Communities study,18
an Australian population-based study,19 the Nurses’
Health study,20 the Physicians’ Health study,7 and the
Health Professionals Follow-up study21 indicated that
patients with DM without a prior history of myocar-
dial infarction have a lower risk of coronary HD events
compared with patients with a history of myocardial
infarction without DM. Although a recent meta-
analysis involving 13 studies with 45,108 patients fol-
lowed up for a duration of 5–25 years concluded that
patients with DM without prior myocardial infarction
have a 43% lower risk of developing total coronary
HD events compared with patients without DM but
with previous myocardial infarction, the meta-analysis
findings cannot be extrapolated to Asian populations
because no relevant Asian studies were included in
the meta-analysis.2
Our study clearly shows that a self-reported HD
increases the risk of CV mortality in subjects with
DM, and the CV mortality risk varies substantially in
subjects with non-HD DM, according to the pres-
ence of HT and MS. It has been recognized that in
females, DM confers a greater risk of coronary HD
risk than in males,22 and the risk increases with the
duration of DM.20 The coronary HD risk may begin
to exceed that of prior myocardial infarction after 15
years of DM.20 Therefore, it is clear that not all
patients with DM have an equivalent risk of future
CV disease, and that it may not be justified to treat all
patients with DM as a secondary prevention, espe-
cially when resources of health care are limited.2
To determine CV disease risks in patients with
DM, individual risk assessment may be necessary.2 In
the present study, the presence of HT substantially
increased the risks of total and CV mortality in sub-
jects with non-HD DM. Therefore, HT may be con-
sidered as a simple and useful marker to stratify risk
for these patients.23 In contrast, the presence of MS
may not substantially increase the risks of total and CV
mortality in subjects with non-HD DM. Although an
increasing prevalence of MS is expected in Asian pop-
ulations,24 our previous study suggested that the
development of HT and/or DM is a necessary step
before MS causes CV mortality.25
The limitations of the present study are as follows.
Subjects with or without HD were categorized based
on a questionnaire. The general public does not know
exactly what HD is and usually considers HD a serious
disease diagnosed only by a physician. Most subjects
who label themselves as having “HD” may have
obtained this impression from some medical profes-
sionals. Most people who do not know about HD or
are not sure if they have HD may simply pick the
answer “I don’t know”. Therefore, a self-reported
history of “HD” usually implies the presence of cer-
tain heart problems that may increase the risk of CV
mortality. In our community surveys, the reply of the
presence of HD from participants might actually imply
the presence of certain heart problems previously sug-
gested or diagnosed by a medical professional. Al-
though the diagnosis of HD was not specified in the
questionnaire and not ascertained by medical records,
the results clearly demonstrated that subjects with
self-reported HD but without DM had a significantly
increased risk for total and CV mortality compared
with subjects without DM or HD. Furthermore, we
also observed that the presence of self-reported HD
significantly increased the risk for CV mortality in
subjects with DM.20
In the present study, the diagnosis of DM was
based on fasting plasma glucose and a history of med-
ication used to facilitate the field work. This approach
might have led to slightly lower estimates of prevalence
than would be obtained from the combined use of fast-
ing plasma glucose and the oral glucose tolerance test.26
A long duration of DM is associated with dramatically
increased risks of death from all causes and fatal
CAD.20 Because the duration of DM was not available,
we were not able to assess its impact on all-cause and
CV mortality.
In conclusion, non-HD DM subjects have similar
risks of CV mortality to non-DM HD subjects in a
J Chin Med Assoc • May 2010 • Vol 73 • No 5240
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Chinese population. The presence of HT but not 
MS substantially increases CV mortality risk in DM
subjects.
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